What should I do if a patient misses a scheduled dose of, or experiences a gap in their long-acting injectable (LAI) treatment?

Please refer to the appropriate section of the FDA label as listed below for each medication. The label can be found by searching Drugs@FDA at the FDA website. Information is also available using the Drugs@FDA smartphone app.

• Abilify Asimtufii (aripiprazole extended-release solution) – Refer to label section 2.3: Missed Doses
• Abilify Maintena (aripiprazole monohydrate LAI) – Refer to label section 2.2: Dosage Adjustments for Missed Doses
• Aristada (aripiprazole lauroxil LAI) – Refer to label section 2.2: Missed Doses
• Invega Hafyera (paliperidone palmitate 6-mo LAI) – Refer to FDA label section 2.3: Missed Doses
• Invega Sustenna (paliperidone palmitate LAI) – Refer to label section 2.3: Missed Doses
• Invega Trinza (paliperidone palmitate 3-mo LAI) – Refer to label section 2.3: Missed Doses
• Perseris (risperidone sub-cutaneous LAI) – Refer to label section 2.1: Recommended Dosage
• Risperdal Consta (risperidone LAI) – Refer to FDA label section 2.1: Schizophrenia/Reinitiation
• Rykindo (risperidone for extended-release solution)  – Refer to label section 2.5: Reinitiation of Treatment in Patients Previously Discontinued
• Uzedy (risperidone for extended-release solution) – Refer to label section 2.1: Recommended Dosage

There is no specific guidance from the FDA on how to handle missed doses of the following LAIs:

• Haldol decanoate (haloperidol LAI)
• Prolixin decanoate (fluphenazine LAI)